AI could help diagnose thyroid nodules

The combination of machine learning and ultrasound could help healthcare providers with the diagnosis of thyroid nodules, according to new findings published in JAMA Otolaryngology.

When thyroid nodules are evaluated, using ultrasound, biopsy and fine-needle aspiration (FNA) are often the next steps. Molecular testing is yet another option. But could AI play a key role in risk stratification for these patients? That’s exactly the question researchers wanted to explore.

“Machine learning is a low-cost and efficient tool that could help physicians arrive to a quicker decision as to how to approach an indeterminate nodule,” co-author John Eisenbrey, PhD, associate professor of radiology at Thomas Jefferson University in Philadelphia, said in a prepared statement. “No one has used machine learning in the field of genetic risk stratification of thyroid nodule on ultrasound.”

The study’s authors trained an algorithm with imaging findings from 121 patients who underwent both ultrasound-guided fine needle-biopsy and molecular testing. Machine learning helped the algorithm “learn” what to look for when evaluating thyroid nodules and was able to achieve a specificity of 97%, predictive positive value of 90% and accuracy of 77.4%.

“This was such an important collaboration of surgeons and radiologists, and there's already interest from other institutions to pool our resources,” said co-author Elizabeth Cottrill, MD, also of Thomas Jefferson University. “The more data we feed the algorithm, the stronger and more predictive we'd expect it to become.”

Eisenbrey added that the researchers are already looking ahead to how they could improve this work in the future. They want to leverage feature extraction, for instance, to “help us identify anatomically relevant features of high-risk nodules.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.